Multidrug resistance (MDR) is a major hurdle to the success of cancer chemotherapy. Poloxamers have been shown to reverse MDR by inhibiting the P-glycoprotein (P-gp) pump. The objective of this research is to test the feasibility of docetaxel-loaded PLGA-TPGS/Poloxamer 235 nanoparticles to overcome MDR in docetaxel-resistant human breast cancer cell line. Docetaxel-loaded nanoparticles were prepared by a modified nanoprecipitation method using PLGA-TPGS and PLGA-TPGS/Poloxamer 235 mixture, respectively. The PLGA-TPGS/Poloxamer 235 nanoparticles were of spherical shape and have a rough and porous surface. The docetaxel-loaded PLGA-TPGS/Poloxamer 235 porous nanoparticles which had an average size of around 180 nm with a narrow size distribution were stable, showing almost no change in particle size and surface charge during the 3-month storage period. The in vitro drug release profile of both nanoparticle formulations showed a biphasic release pattern. There was an increased level of uptake of PLGA-TPGS/Poloxamer 235 porous nanopartides (PPNPs) in docetaxel-resistant human breast cancer cell line, MCF-7/TXT, in comparison with PLGA-TPGS nanoparticles (PTNPs). The PLGA-TPGS/Poloxamer 235 porous nanoparticles produced significantly higher level of toxicity than both of PLGA-TPGS nanoparticle formulation and Taxotere (R) both in vitro and in vivo, indicating docetaxel-loaded PLGA-TPGS/Poloxamer 235 porous nanoparticles have significant potential for the treatment of breast cancer. (C) 2015 Elsevier B.V. All rights reserved.
基金：
Beijing Top Level Health Scientific Innovation Personnel Training Plan [2013-3-047]; Open Research Fund Program of the State Key Laboratory of Virology of China [2014KF004]; National High Technology Research and Development Program (863 Program)National High Technology Research and Development Program of China [2011AA02A111]
第一作者机构：[1]Anhui Univ Sci & Technol, Sch Med, Stem Cell Engn Res Ctr, Huainan 232001, Peoples R China;[2]Tianjin Int Joint Acad Biomed, Tianjin 300457, Peoples R China;[3]Capital Med Univ, Beijing Tiantan Hosp, Dept Anesthesia & Pain Therapy, Beijing 100050, Peoples R China;
通讯作者：
通讯机构：[3]Capital Med Univ, Beijing Tiantan Hosp, Dept Anesthesia & Pain Therapy, Beijing 100050, Peoples R China;
推荐引用方式(GB/T 7714)：
Tang Xiaolong,Liang Yong,Feng Xiaojun,et al.Co-delivery of docetaxel and Poloxamer 235 by PLGA-TPGS nanoparticles for breast cancer treatment[J].MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS.2015,49:348-355.doi:10.1016/j.msec.2015.01.033.
APA：
Tang, Xiaolong,Liang, Yong,Feng, Xiaojun,Zhang, Rongbo,Jin, Xu&Sun, Leilei.(2015).Co-delivery of docetaxel and Poloxamer 235 by PLGA-TPGS nanoparticles for breast cancer treatment.MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS,49,
MLA：
Tang, Xiaolong,et al."Co-delivery of docetaxel and Poloxamer 235 by PLGA-TPGS nanoparticles for breast cancer treatment".MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS 49.(2015):348-355
